# Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 5, 2025

## EGFR (A-10)

RRID:AB_10920395
Type: Antibody

### Proper Citation

(Santa Cruz Biotechnology Cat# sc-373746, RRID:AB_10920395)

### Antibody Information

**URL:** http://antibodyregistry.org/AB_10920395

**Proper Citation:** (Santa Cruz Biotechnology Cat# sc-373746, RRID:AB_10920395)

**Target Antigen:** EGFR (A-10)

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** validation status unknown check with seller; recommendations: WB, IP, IF, ELISA

**Antibody Name:** EGFR (A-10)

**Description:** This monoclonal targets EGFR (A-10)

**Target Organism:** rat, mouse, human

**Antibody ID:** AB_10920395

**Vendor:** Santa Cruz Biotechnology

**Catalog Number:** sc-373746

**Record Creation Time:** 20241016T235512+0000

**Record Last Update:** 20241017T012620+0000

### Ratings and Alerts

No rating or validation information has been found for EGFR (A-10).

No alerts have been found for EGFR (A-10).

## Data and Source Information

**Source:** Antibody Registry

## Usage and Citation Metrics

We found 15 mentions in open access literature.

**Listed below are recent publications.** The full list is available at FDI Lab - SciCrunch.org.


Cigrang M, et al. (2025) Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity. Nature communications, 16(1), 512.

Dilday T, et al. (2024) Identification and characterization of a potent and selective HUNK inhibitor for treatment of HER2+ breast cancer. Cell chemical biology.

Popovi? L, et al. (2024) Profiling of ERBB receptors and downstream pathways reveals selectivity and hidden properties of ERBB4 antagonists. iScience, 27(2), 108839.

Dimitrov J, et al. (2024) Dynamic roles of neutrophil extracellular traps in cancer cell adhesion and activation of Notch 1-mediated epithelial-to-mesenchymal transition in EGFR-driven lung cancer cells. Frontiers in immunology, 15, 1470620.

Ko A, et al. (2023) LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL. Cancer discovery, 13(3), 702.

Tyc KM, et al. (2023) Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers. iScience, 26(3), 106082.

Jiang Q, et al. (2023) HPIP is an essential scaffolding protein running through the EGFR-RAS-ERK pathway and drives tumorigenesis. Science advances, 9(23), eade1155.

Asuzu DT, et al. (2022) Pituitary adenomas evade apoptosis via noxa deregulation in Cushing's disease. Cell reports, 40(8), 111223.

Cai S, et al. (2022) Multiplexed protein profiling reveals spatial subcellular signaling networks. iScience, 25(9), 104980.

Hanasoge Somasundara AV, et al. (2021) Parity-induced changes to mammary epithelial cells control NKT cell expansion and mammary oncogenesis. Cell reports, 37(10), 110099.

McFall T, et al. (2021) Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. Cell reports, 37(11), 110096.

Markworth R, et al. (2021) Tubular microdomains of Rab7-positive endosomes retrieve TrkA, a mechanism disrupted in Charcot-Marie-Tooth disease 2B. Journal of cell science, 134(20).

Rodger C, et al. (2020) De Novo VPS4A Mutations Cause Multisystem Disease with Abnormal Neurodevelopment. American journal of human genetics, 107(6), 1129.

Leelatian N, et al. (2020) Unsupervised machine learning reveals risk stratifying glioblastoma tumor cells. eLife, 9.

Yammine L, et al. (2019) Lipocalin-2 Regulates Epidermal Growth Factor Receptor Intracellular Trafficking. Cell reports, 29(7), 2067.